Zurück zur Übersicht
| Haematologica. 2014 Oct 24. pii: haematol.2014.110452. doi: 10.3324/haematol.2014.110452 |
| Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. |
| Braulke F1, Platzbecker U2, Müller-Thomas C3, Götze K4, Germing U5, Brümmendorf TH6, Nolte F7, Hofmann WK8, Giagounidis AA9, Lübbert M10, Greenberg PL11, Bennett JM12, Solé F13, Mallo M14, Slovak ML15, Ohyashiki K16, Le Beau MM17, Tüchler H18, Pfeilstöcker M19, Nösslinger T20, Hildebrandt B21, Shirneshan K22, Aul C23, Stauder R24, Sperr WR25, Valent P26, Fonatsch C27, Trümper L28, Haase D29, Schanz J30 |
 Author information
|
|
Abstract International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34(+) peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34(+) blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913). |
|
Copyright© Ferrata Storti Foundation. |
|
Publikations ID: 25344522 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
